Effect of tirzepatide on gut health after stopping in obese patients
Treatments studied
Part of Hormones & metabolism clinical trials.
This study looks at how a weight-loss drug called tirzepatide affects your gut bacteria and digestion after you stop taking it. If you are obese and about to start this drug, joining might help you understand how it changes your body.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 65 years old.
- You are either in the obese treatment group: have a BMI of 30 or higher, or a BMI of 27 or higher with an obesity-related problem (like high blood pressure or diabetes).
- Your doctor has determined you need tirzepatide (a weight-loss drug) and plans to start it as part of your normal care.
- You have not taken antibiotics, probiotics, or prebiotics in the last 3 months.
- You do not have a severe bowel condition, recent bowel surgery, or serious liver/kidney disease.
- You are not pregnant, breastfeeding, or have had a recent acute infection.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether tirzepatide, a medication that helps with weight loss and blood sugar control, can improve the ability to exercise and daily function in people who have heart failure with reduced pumping strength and are overweight or obese.
This study looks at how genes, gut bacteria, and lifestyle behaviors relate to weight. Researchers will test a weight-loss medication (tirzepatide) as part of the study to see if it helps people with overweight or obesity.
This study looks at how well the medicine tirzepatide works in real life for adults who are overweight (BMI 30 or more) and have prediabetes or type 2 diabetes. It aims to see if the medicine helps control blood sugar and weight, and it's important that you have had a recent eye exam before starting.
This study tests whether combining a weight-loss medication called tirzepatide (also known as Mounjaro) with a supervised exercise program helps people lose weight and improve their overall health. You'll be in the study for about four months, and you'll get support and monitoring.
This study tests whether the medicine tirzepatide can help adults who are overweight or obese and have congenital heart disease (a heart condition present from birth) lose weight safely. The medicine may also improve heart health and metabolism. It is for people who have already tried diet and exercise for at least a year without much weight loss.
This Phase 2 study tests whether tirzepatide can improve how your body handles fat (especially in people with overweight or obesity) and reduce fat-related “lipotoxicity.” It may help with body fat function and related health markers, but you must meet specific health and medication rules.
Hear when a new Obesity & Overweight trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.